Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy
Top Cited Papers
- 1 December 2010
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 56 (25), 2115-2125
- https://doi.org/10.1016/j.jacc.2010.07.033
Abstract
No abstract availableKeywords
Funding Information
- Intramural Research Program of the NIH/NIAAA (DA9789)
- NIDA
- Novartis
This publication has 33 references indexed in Scilit:
- The emerging role of the endocannabinoid system in cardiovascular diseaseSeminars in Immunopathology, 2009
- The Role of Poly(ADP-Ribose) Polymerase Activation in the Development of Myocardial and Endothelial Dysfunction in DiabetesDiabetes, 2002
- IGF-1 Overexpression Inhibits the Development of Diabetic Cardiomyopathy and Angiotensin II–Mediated Oxidative StressDiabetes, 2001
- The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritisProceedings of the National Academy of Sciences, 2000
- Comparative receptor binding analyses of cannabinoid agonists and antagonists.1998
- Diabetic cardiomyopathy: experimental and clinical observations.1994
- Controlled clinical trial of cannabidiol in Huntington's diseasePharmacology Biochemistry and Behavior, 1991
- Diabetic CardiomyopathyDiabetes Care, 1990
- Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic PatientsPharmacology, 1980
- Isolation and structure of .DELTA.+- tetrahydrocannabinol and other neutral cannabinoids from hashishJournal of the American Chemical Society, 1971